Paolo Caimi, MD
Enriched profileProfessor of Medicine and hematologic oncologist at Cleveland Clinic Cancer Institute · Cleveland Clinic
Paolo Caimi is Professor of Medicine and hematologic oncologist at Cleveland Clinic Cancer Institute at Cleveland Clinic. OpenAlex indexes 480 publications with 8,619 citations (h-index 44); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 24 Oct 2026
Paolo Caimi, M.D., is Professor of Medicine and hematologic oncologist at Cleveland Clinic Cancer Institute. The public record shows 480 publications with 8,619 citations (h-index 44), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 21 companies.
- Most recent indexed publication: 2025 · Blood advances
- Top research focus: Lymphoma Diagnosis and Treatment
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 115.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Collection of Peripheral Blood From Patients With Hematologic Malignancies With Thrombocytopenia
Sponsor: Case Comprehensive Cancer Center
Industry payments
Updated 24 Oct 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Genentech, Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20253 payments
- ADC THERAPEUTICS AMERICA, INC.Program year20258 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.9%Kinase inhibitor31.3%Brukinsa66%Imbruvica25%Jaypirca8%Part D<11 patientsBCL-2 Inhibitor5.6%Venclexta100%Part D<11 patientsDermatology
22%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22%Acyclovir100%Part D≥34 patientsMetabolism & gastrointestinal
14.1%Corticosteroid9.2%Prednisone100%Part D≥25 patientsH2 blocker2.8%Famotidine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 24 Oct 2026
139 congress contributions (2012–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL).
ASCO Annual Meeting
ASCO2026Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Lenalidomide, rituximab (R(2)), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
Leukemia & lymphoma
Clinical Trial2024 - Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models.
Cancer immunology research
Comment2024
Most-cited works
by citation count (OpenAlex)- 01Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyArticle1,726 citations2020
- 02
- 03
- 05The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial DesignArticle225 citations2020
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 24 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/paolo-caimi-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
bloodcancerunited.org/award-recipient/paolo-caimi-0
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerunited.org ↗ - Other
bottomlineinc.com/source/paolo-caimi-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bottomlineinc.com ↗ - Other
providers.clevelandclinic.org/provider/paolo-caimi/4269580
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗ - Other
vumedi.com/video/ash-2024-review-key-updates-in-non-hodgkin-lymphoma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vumedi.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.clevelandclinic.org ↗
Secondary affiliations
appointments beyond the home institution- Case Comprehensive Cancer Center
Case Western Reserve University [current] (ORCID-declared, supplied in task)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - Associate professor
Case Western Reserve University School of Medicine (older third-party directory listing)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
- Cleveland Clinic Cancer Advances podcast
new developments and clinical trials in cell therapy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →my.clevelandclinic.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Nissen, MD
Cleveland Clinic
Samir Kapadia, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Serpil Erzurum, MD
Cleveland Clinic
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Thomas Witzig, MD
Mayo Clinic
Wyndham Wilson, MD
National Cancer Institute (NCI)